Results you can trust
ELM Genomics is a spin-off from Harvard University with a strong academic team harboring expertise in the fields of molecular biology, genetics, biochemistry, biostatistics, and bioinformatics.
Internationally selected
ELM Genomics has been qualified to be one of the disruptive startups among 2022 batch of HealthCareLab International Acceleration program powered by Roche, EIT Health, CIVITTA, and European Union.
LEARN MORE
Our Product Portfolio
İlk-Bakış: Supplemental Newborn DNA Screening
İlk-Bakış is a highly accurate test that analyzes your baby’s DNA for more than 190 conditions that can affect children before the age of 10. It only screens for conditions that may be treated with medication, dietary modification, or other therapies. Our test can also be applied to adults to detect carrier status.
[Click for our brochure] [Click for a sample report]
İlk-Bakış: Adult Carrier Screening
“İlk-Bakış: Adult Carrier Screening” test is designed for our adult customers to identify the potential carrier status for the same 180 diseases/genes with lethal consequences that “İlk-Bakış Newborn Screening” screens for, allowing the parents or the future parents to benefit from family planning.
İleri-Bakış: Health & Lifestyle
İleri-Bakış empowers our users to learn the most from their DNA and improve their physical and mental health by optimizing their lifestyle decisions. Our proprietary algorithm built upon Population Genetics scientific literature quantifies the tendencies for personality, fitness, skin care and nutrition. We further offer our customers to consult with an expert psychologist and take complementary non-genetic well-established personality tests and discuss over their results combining the “nature & nurture” first time in the field.
Doğru-İlaç & Etkin-Dozaj : Pharmacogenetics
Discover how your body would respond to more than 40 medications. Find out whether you are likely to experience side effects or sensitivity to some of the commonly prescribed antibiotics, analgesics, anticoagulants, anticonvulsants, antiemetics, antifungal agents, antidepressants, antilipemic agents, antineoplastic agents, antiplatelet agents, antipsychotics, antiretrovirals, immunosuppressants, enzyme inhibitors, and psychotropics. This analysis can help doctors personalize your treatment throughout your life.
This product is currently under development.
Tam-İsabet: Cancer Genomic Profiling
No two tumors are alike, even within the same patient. Tam-İsabet screens for the driver mutations within tumors of cancer patients with the ultimate goal of identifying the chemotherapeutic agents that their cancer would respond to strictly following FDA guidelines.
This product is currently under development.
Why İlk-Bakış Newborn Screening?
individuals are struggling
with rare diseases
across globe.
are children.
will not survive to see
their 5th birthday.
Problems?
Insufficient screening
Most state-mandated nation-wide newborn screening programs screen for only 5 to 50 conditions.
The danger overlooked
The unscreened but lethal genetical conditions lead to premature child deaths, irreversible mental retardation and permanent phsyical disabilities.
Parents under pressure
Underdiagnosis or extremely long diagnostic odysseys generate psychological and economical burden on parents at micro-scale, and on state and healthcare system at macro-scale.
Genetic unawareness
Lack of genetic awareness and carrier status in societies render family planning infeasible, exacerbating the problem.
The Solution:
Every baby is unique.
Get prepared and informed early about the genetic conditions your child might carry, and take action in time.
